Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Director · CEO and President | August 20, 2024 | August 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PURE BIOSCIENCE, INC.
Report date August 20, 2024 · Filed August 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.07 · Expires 2034-08-20 | Direct | 155,000 |
Reported balance
After 2024-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-20 · Grant · Acquired 155,000 · Balance 155,000 F1: The option shares shall vest and become exercisable in four equal installments on November 20, 2024, February 20, 2025, May 20, 2025, and August 20, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.07 · Expires 2034-08-20 | Direct | 500,000 |
Reported balance
After 2024-08-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-20 · Grant · Acquired 500,000 · Balance 500,000 F2: The option shares are fully vested as of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest and become exercisable in four equal installments on November 20, 2024, February 20, 2025, May 20, 2025, and August 20, 2025.
F2: The option shares are fully vested as of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2024 Filed Aug 22, 2024 21:58 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001493152-24-033619 · ownership.xml · derivative · entry 2 BARTLETT ROBERT F · CIK 0001240229 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-08-20 F2 · derivative.exercise_date: The option shares are fully vested as of the date of grant. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 21:58 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001493152-24-033619 · ownership.xml · derivative · entry 1 BARTLETT ROBERT F · CIK 0001240229 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2034-08-20 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on November 20, 2024, February 20, 2025, May 20, 2025, and August 20, 2025. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:13 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-23-044408 · doc4.xml · derivative · entry 1 BARTLETT ROBERT F · CIK 0001240229 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on November 1, 2023, February 1, 2024, May 1, 2024, and August 1, 2024. Read SEC document |
| March 22, 2023 Filed Mar 22, 2023 21:53 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 50,000 | $0.16 | $7,750.00 |
DisclosureSEC source: 0001209191-23-020592 · doc4.xml · nonDerivative · entry 1 BARTLETT ROBERT F · CIK 0001240229 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Bartlett Living Trust U/A DTD 07/01/1991 Disclosed balance after: 50,000 F1 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $0.13 to $0.1599. The price reported in this column reflects the weighted average purchase price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: Mr. Bartlett is a trustee of the Bartlett Living Trust U/A DTD 07/01/1991 and has voting and dispositive power with respect to these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.